20/20 Onsite

Home
United States
Boston, MA
20/20 Onsite

20/20 Onsite delivers comprehensive eye exams to businesses via a state-of-art mobile vision center.

20/20 Onsite (also known as 2020 Onsite) is the only provider solely dedicated to point-of-need eye assessments for clinical trials, proven to meet screening timelines, improve retention rates, and fast-track trials. This is a great way for companies to offer a unique, low-cost benefit to employees.

03/19/2026

Before awarding new studies, sponsors and CROs frequently rely on ex*****on references, not just published outcomes. Data quality, consistency, and coordination shape those conversations.

20/20 Onsite protects both audiences:
Regulatory rigor that supports compliant submissions
Consistent ex*****on that stands up in reference checks
Single-partner accountability that eliminates operational ambiguity

Your endpoints do not just close a trial.

They shape your reputation for the next one.

https://hubs.ly/Q046pkcf0

03/17/2026

“We lost another participant.”
The reason? The visit required a 90-minute drive each way.
For most patients, that’s simply too far.

📊 Research backs it up: most patients are only willing to travel ~30 minutes or ~22 miles (PubMed).

At 20/20 Onsite, we decided to flip the model. Instead of waiting for patients to come to the site, we bring the site to them.

Our Mobile Vision Clinics deliver exams in patients’ own communities, reducing average travel distance by 82%.

When you remove travel as a barrier, participation rates rise, retention improves, and trials finish faster.

Close the gap. Capture the patient.

03/12/2026

The clinical trial diversity challenge isn't a recruitment problem—it's an access architecture problem.

When FDA guidance pushes for representative enrollment, the bottleneck isn't participant's willingness. It's the infrastructure assumption that everyone can reach fixed sites on rigid schedules.

Consider what's required to participate in a six-month ophthalmic study at a traditional center:
→ Transportation to unfamiliar locations
→ Time away from employment without flexibility
→ Childcare coordination for recurring visits
→ Navigation of institutional healthcare settings

These aren't minor inconveniences.

Mobile clinical infrastructure inverts the equation. Instead of asking communities to come to research, the research adapts to community realities. The result isn't just broader demographics in your enrollment data; it's retention rates that reflect genuine accessibility.

When participants can complete protocol visits near home, on schedules that accommodate their lives, with staff trained in cultural competency, the retention gap narrows dramatically.

This matters beyond compliance metrics. Medical interventions tested only on populations with the resources to access traditional sites produce evidence gaps that carry forward into real-world treatment efficacy.

Representative research requires representative infrastructure.

Details on operational models here: https://hubs.ly/Q0433vLr0

03/11/2026

Retention challenges are often addressed with added interventions.
Calls. Reminders. Incentives.

Yet the root cause is frequently unchanged: participation remains inconvenient.

20/20 Onsite improves retention by redesigning how care is delivered:
Assessments at the point of need
Predictable, standardized visits
Minimal coordination burden for participants

Retention improves when the path of least resistance is also the compliant one.

03/09/2026

There is something powerful about getting the entire team in one room.

Last week at our 20/20 Onsite all-hands meeting, we spent time reflecting on the past year, the milestones we reached, and the impact our team continues to make supporting clinical trials across the country.

More importantly, we aligned around where we are going next.
The energy, collaboration, and commitment to our mission was clear across every conversation.

Helping sponsors and CROs succeed while keeping patients at the center of what we do takes a special kind of team.

After last week, we are more aligned and energized than ever for the year ahead.

03/04/2026

Four months. That’s the average delay when a protocol amendment hits your trial.

And with over 40% of trials requiring one, those “small adjustments” can become million-dollar slowdowns.

Inconsistent site training, variable assessments, and equipment differences — they all add noise that forces rework.

At 20/20 Onsite, we eliminate that variability from the start.
Our standardized, mobile, point-of-need ocular assessments ensure every site, every visit, and every patient follow the same playbook.

The result? Cleaner data. Fewer amendments. Faster launches.

03/02/2026

When FDA-mandated ophthalmic assessments threaten to derail your trial, you need more than hope; you need an operational rescue playbook.

Join Jessica McKenzie, VP of Life Sciences at 20/20 Onsite, for this exclusive on-demand webinar where she shares the proven strategies behind 85,000+ exams, 40+ trials, and 100% on-time delivery.

Learn how to identify enrollment stalls and capacity constraints early, apply immediate operational fixes for trial continuity, and know when to adjust versus redesign your protocols.

Plus, get access to a zero-commitment, 24-hour study assessment to evaluate your trial's current risk profile.

Watch now → https://hubs.ly/Q041LRHx0

02/26/2026

You don't need to redesign your entire protocol when ocular endpoints are at risk.

What you need is a systematic triage playbook you can deploy today.

In this on-demand webinar, Jessica McKenzie, VP of Life Sciences at 20/20 Onsite, shares the exact framework trusted by 40+ clinical trials to detect early warning signals, execute immediate triage, and deploy point-of-need capacity without compromising data quality or timelines.

Walk away with a reusable protocol checklist and access to a zero-commitment, 24-hour study assessment.

Click here to watch the webinar → https://hubs.ly/Q03Zxm290

02/25/2026

Site Initiation Visits (SIVs) are where ocular endpoints either get set up for clean, consistent ex*****on, or quietly pick up the “small problems” that turn into timeline slips, data variability, and avoidable rework later.

A few SIV focuses that matter more than most teams expect:

- Training and certification: BCVA, OCT, IOP, these are not “plug and play.” Standardization is the work.
- Device validation and readiness: calibration, documentation, and traceability need to be audit-ready from day one.
- Vendor coordination and data flow: if device data to CRF/EDC is not mapped early, you will feel it at go-live.

If you are building in ocular endpoints, treat the SIV as your operational design review, not a checkbox.

Read the full breakdown here. https://hubs.ly/Q041h4L70

02/19/2026

The shift toward decentralized trial models surfaces a fundamental tension: ophthalmic endpoints require precision equipment and controlled conditions, yet participant-centric design demands flexibility and reduced burden.

This isn't a tradeoff you solve by compromising on one side.

Virtual-only approaches introduce measurement variability that regulatory bodies scrutinize. Traditional fixed-site models create participation barriers that undermine enrollment and retention targets.

The strategic middle ground is distributed clinical infrastructure, mobile units that bring laboratory-grade conditions to participants rather than asking participants to reach laboratories.

What this requires operationally:
→ Endpoint mapping to identify which assessments demand-controlled environments
→ Equipment standardization across all deployment locations
→ Technician certification that ensures procedural consistency
→ Documentation systems designed for regulatory audit trails

The implementation complexity is real. But so is the enrollment of velocity when you remove the burden of repeated distant travel from protocol participation.

And retention metrics shift substantially when participants experience research as something designed around their lives rather than something that disrupts them.

The question for sponsors isn't whether to decentralize. It's how to decentralize while maintaining the measurement integrity that phase 3 endpoints require.

Framework details: https://hubs.ly/Q03ZQyZv0

02/18/2026

Meet Dr. Kamrian Wilson and Dr. Aubrey Wilson, a mother-daughter optometry duo bringing care, compassion, and a shared passion for patients to 20/20 Onsite's clinical trial network in Missouri.

Dr. Kamrian Wilson's Story:
"I first became involved with 20/20 Onsite when Dr. Alina Reznik reached out on ODs on Facebook asking whether anyone in the Dixon, Missouri area was able to see a child for any ocular evaluation. My practice is just 20 minutes away so I responded, I would be happy to help! I was paid for this, but I would have done it at no charge if needed, just to help this patient remain on a life changing medication."

What keeps her coming back?
"I love working with 20/20 Onsite! The team, including doctors, ophthalmic technicians, and others, are wonderful and passionate about what they do!"

Her philosophy on clinical trial work?
"I feel to work in clinical trials, beyond performing excellent eye care, is a passion for the profession but most importantly a passion for each individual you see."

Dr. Aubrey Wilson's Story:
Following in her mother's footsteps, Dr. Aubrey Wilson joined the 20/20 Onsite network:
"My mom, Kami Wilson, recommended the job to me. It sounded like a great experience to add to my regular job."

What does she love most about the work?
"Getting to meet a variety of patients in an environment with less time pressure. I also enjoyed the free time between patients."

Her most memorable experience captures the heart of family legacy:
"Meeting a patient who had last been examined by my mom Kami, and the patient remembering her. We had a great experience talking together that day."

The Wilson family story reminds us that 20/20 Onsite's OD Network is more than just flexible work; it's meaningful work worth recommending to the people you care about most.

Are you an OD looking for:
+ Flexible opportunities that complement your existing practice
+ Meaningful work helping patients access life-changing medications
+ A supportive, passionate team environment
+ The chance to make a real difference in clinical research

📩 Interested in learning more? Email Dr. Katherine Harkins, Director of Optometry, at kharkins@2020onsite.com

02/16/2026

Ask any Clinical Ops lead what slows a study and most will say the same thing: enrollment.

📊 9 out of 10 clinical trials ultimately double their original timelines just to meet enrollment targets (Antidote).

It’s not for lack of effort - it’s logistics. Travel burdens, missed screenings, delayed site activations. It all adds up fast.

At 20/20 Onsite, we remove those barriers. Our nationwide, Mobile Vision Clinics bring advanced, point-of-need ocular assessments directly to patients.

That means faster screenings, smoother enrollment, and studies that stay on schedule.

Address

Boston, MA
02110

Website

http://www.2020onsite.com/

Alerts

Be the first to know and let us send you an email when 20/20 Onsite posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to 20/20 Onsite:

Shortcuts

Want your practice to be the top-listed Clinic in Boston?